Regarding the treatment monitoring of NSCLC patients, a comprehensive analysis of EGFR mutations in cfDNA and CTCs could be more informative as this was recently demonstrated in studies that included both LB analytes (66, 67). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.